Universität zu Köln

Kreissl, S., Eichenauer, D. A., Meissner, J., Topp, M. S., Engert, A. and Borchmann, P. (2018). New developments in the treatment of advanced classical Hodgkin's lymphoma. Onkologe, 24 (4). S. 315 - 322. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Full text not available from this repository.

Abstract

With the current standard of care of the German Hodgkin Study Group (DHSG) consisting of interim positron emission tomography (PET)-guided administration of 4-6 cycles of BEACOPP(escalated) (escalated-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) plus radiotherapy of PET-positive residual lymphoma, the overall survival (OS) of patients with advanced Hodgkin's lymphoma (HL) is in excess of 95%; however, further minimization of acute and delayed toxicities without compromising the tumor-specific outcome of patients is needed, as defining the right balance between efficacy and toxicity remains the most important challenge in HL. The aim of this article is to provide an overview of the current standard of care and recent developments in the treatment of advanced HL. By a systematic literature search, relevant publications as well as reports on new approaches that are being evaluated in current trials were collated and are summarized. Recent comparisons of BEACOPP(escalated) and ABVD (Doxorubicin, Bleomycin, Vinblastin, Dacarbazin) regimens showed a substantial benefit of BEACOPP(escalated) in terms of progression-free survival (PFS) and OS. The interim PET-guided administration of 4-6 cycles of BEACOPP(escalated) can be considered a safe, feasible and highly active approach. This strategy might be improved by the implementation of targeted drugs, such as brentuximab vedotin; therefore, standard BEACOPP(escalated) is currently randomly compared with a variant named Brentuximab Vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD), which was previously shown to be safe and feasible in a phase II study. The major goal in the treatment of advanced HL is the minimization of toxicity without compromising efficacy. Targeted drugs might replace unspecific cytotoxic drugs, which cause systemic toxicity. Hence, the antibody-drug conjugate brentuximab vedotin is currently being investigated as a component of the BEACOPP variant BrECADD in the randomized DHSG HD21 trial.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Kreissl, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichenauer, D. A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Meissner, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Topp, M. S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-190152
DOI:	10.1007/s00761-018-0342-y
Journal or Publication Title:	Onkologe
Volume:	24
Number:	4
Page Range:	S. 315 - 322
Date:	2018
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1433-0415
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INTERNATIONAL PROGNOSTIC SCORE; BRENTUXIMAB VEDOTIN; OPEN-LABEL; TRIAL; ABVD; INTERGROUP; SURVIVORS; THERAPY; INTERIM; SGN-35 Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/19015